July 12, 2021

We are pleased to announce that Professor James [Jim] Lorens has joined Papyrus Therapeutics as an independent director of the company.  Jim has wide experience in the academic and biotech sectors and will bring tremendous insight to the Papyrus Board, having undertaken postdoctoral work at Stanford University studying tumor and immune cell apoptosis mechanisms, before joining Rigel Pharmaceuticals in 1997. As one of the first scientists at Rigel, Professor Lorens led technology development and was later Director of Oncology R&D. He founded BerGenBio AS in 2007 to facilitate clinical translation of his group’s pioneering research on the Axl receptor tyrosine kinase and served as their Chief Scientific Officer. BerGenBio’s Axl inhibitor (BGB324) is currently in Phase I/II clinical trials for the treatment of cancer.

He is currently Professor in the Department of Biomedicine at the University of Bergen Faculty of Medicine, Norway and principal investigator at the Center for Cancer Biomarkers, Norwegian Center of Excellence. He is also a member of the Norwegian Academy of Sciences and Letters.

In addition to his academic research, university teaching and supervisory activities, Prof. Lorens has served on several Editorial Boards, government R&D policy commissions and the Norwegian Research Council Boards on Innovation and Health Research.


Dr. Paul Blake